Novel Crystalline Pharmaceutical Product

• US 20090124585A1
• Filed: 04/06/2006
• Published: 05/14/2009
• Est. Priority Date: 04/08/2005
• Status: Abandoned Application

• Current Assignee: Glaxo Group Limited (Glaxosmithkline Holdings Ltd.)
• Original Assignee: Glaxo Group Limited (Glaxosmithkline Holdings Ltd.)
• Inventors: Price, Christopher John, Hannan, Matthew Lawrence, Lee, Mei-yin, Cross, Wendy Isabel, Johns, David Michael
• Application Number:
  US11/910,615
• Publication Number:
  US 20090124585A1
• Time in Patent Office: Days
• US Class Current: 514/172
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 11/06 Antiasthmatics
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/04 Antipruritics
• CPC Class Codes: A61P 17/06 Antipsoriatics
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 27/16 Otologicals
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 37/08 Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: B01D 9/0036 Crystallisation on to a bed of product crystals; Seeding
• CPC Class Codes: B01D 9/005 Selection of auxiliary, e.g. for control of crystallisation nuclei, of crystal growth, of adherence to walls; Arrangements for introduction thereof
• CPC Class Codes: C07J 31/006 not covered by C07J31/003

Abstract

There are provided crystalline particles of unsolvated Form 1 polymorph of the compound of formula (I):

characterised in that the particles are in the form of substantially triangular plates.

Claims

1. Crystalline particles of unsolvated Form 1 polymorph of the compound of formula (I):

characterised in that the particles are in the form of substantially triangular plates.

2. Crystalline particles as claimed in claim 1

characterised in that the particles are in the form of triangular plates.

3. Crystalline particles as claimed in claim 1 wherein the angles of the triangular faces are approximately 80°

, 50° and

50°

.

4. Crystalline particles as claimed in claim 1, of size 0.1-0.2 μ

m×

4-5 μ

m×

4-5 μ

m.

5. A pharmaceutical composition comprising crystalline particles according to claim 1 admixed with a physiologically acceptable diluent or carrier.

6. A pharmaceutical composition according to claim 5 in dry powder form wherein the diluent or carrier is particulate lactose.

7. A method for the treatment of a human or animal subject with an inflammatory and/or allergic condition, which method comprises administering to said human or animal subject an effective amount of crystalline particles according to claim 1.

8. A pharmaceutical composition comprising crystalline particles according to claim 1 in combination with another therapeutically active agent.

9. A pharmaceutical composition according to claim 8 wherein the other therapeutically active ingredient is a long acting β

₂-adrenoreceptor agonist.

18. The method of treatment as claimed in claim 7, wherein said effective amount is delivered to the human or animal once-per-day.

10. A process for preparing crystalline particles of unsolvated Form 1 polymorph of the compound of formula (I):

wherein the particles are in the form of substantially triangular plates, which process comprises dissolving the compound of formula (I) in a solvent of methyl-isobutyl-ketone (MIBK) containing between 1 and 15% v/v methyl-ethyl-ketone (MEK), and

producing compound of formula (I) as unsolvated Form 1 polymorph by addition of heptane as anti-solvent.

11. A process for preparing crystalline particles according to claim 10,

wherein the particles are in the form of triangular plates.

12. A process according to claim 10 wherein the solvent contains between 5% and 15% v/v MEK.

13. A process according to claim 12 wherein the solvent contains MIBK and MEK in a ratio of 9:

1 v/v.

14. A process according to claim 10 wherein the particles are prepared in a continuous process in the presence of ultrasonic radiation.

15. A population of crystalline particles of unsolvated Form 1 polymorph of the compound of formula (I):

obtainable by the process of claim 14.

16-17. -17. (canceled)

19. An apparatus adapted to prepare crystalline particles of a substance which comprises:

(i) a first reservoir adapted to contain said substance dissolved in a liquid solvent;

(ii) a second reservoir adapted to contain liquid anti-solvent for said substance which is miscible with the liquid solvent;

(iii) a first mixing chamber having first and second inlet ports, an outlet port and a source of ultrasonic radiation;

(iv) a second mixing chamber having a first inlet port adapted for fluid connection with the outlet port of the first mixing chamber such that liquid exiting the first mixing chamber flows into the second mixing chamber, a second inlet port adapted for fluid connection with the antisolvent reservoir, an outlet port and a source of ultrasonic radiation;

(v) means for delivering the contents of the first reservoir to the first mixing chamber via the first inlet port, and means for delivering the contents of the second reservoir to the first and second mixing chambers via the second inlet ports; and

(vi) means for collecting particles suspended in the liquid discharged from the outlet port of the second mixing chamber.